Ariya-Atthaya Pakveranun, Pureesrisak Purit, Meephansan Jitlada, Charoensuksira Sasin, Sirithanabadeekul Punyaphat, Thanasarnaksorn Wilai, Tantisantisom Kittipong, Thongma Sattra, Rayanasukha Yossawat, Khanchaitit Paisan, Suchonwanit Poonkiat
Division of Dermatology, Chulabhorn International College of Medicine, Thammasat University, Rangsit Campus, Klong Luang, Pathum Thani, Pathum Thani, 12120, Thailand.
Division of Dermatology, Department of Medicine, Rajavithi Hospital, Ministry of Public Health, Bangkok, 10400, Thailand.
Arch Dermatol Res. 2025 Jun 9;317(1):804. doi: 10.1007/s00403-025-04307-7.
Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss. Current treatment options, such as intralesional corticosteroid (ILCS) injections, are effective but often associated with adverse effects, including pain, skin atrophy, and reduced patient compliance. This study investigates the efficacy and safety of a corticosteroid-loaded microneedle patch as an alternative treatment modality for AA.
A prospective experimental study was conducted on patients diagnosed with patch-type AA. Participants received treatment at intervals of 4-6 weeks for a total duration of 24-36 weeks using a corticosteroid-loaded microneedle patch. Treatment efficacy and safety were evaluated using hair regrowth scales, dermoscopic findings, and pain scores.
The study enrolled 14 participants, totaling 24 treated patches. Significant hair regrowth was observed, with a mean regrowth scale (RGS) increasing to 2.4 by the 16-24 week period and reaching 4 by 24-36 weeks. Dermoscopic analysis showed reductions in black dots and yellow dots, while vellus hairs increased. Mean pain scores remained low throughout treatment, ranging from 1.00 to 3.00, highlighting the treatment's good tolerability compared to traditional intralesional injections.
Microneedle patch-based corticosteroid delivery demonstrated efficacy comparable to ILCS injections, with the added advantage of reduced treatment-related pain and potentially enhanced patient compliance.
斑秃（AA）是一种以非瘢痕性脱发为特征的自身免疫性疾病。目前的治疗方法，如皮损内注射皮质类固醇（ILCS），虽然有效，但常常伴有不良反应，包括疼痛、皮肤萎缩以及患者依从性降低。本研究调查了一种载有皮质类固醇的微针贴片作为斑秃替代治疗方式的有效性和安全性。
对诊断为斑块型斑秃的患者进行了一项前瞻性实验研究。参与者使用载有皮质类固醇的微针贴片，每隔4 - 6周接受一次治疗，总疗程为24 - 36周。使用毛发再生量表、皮肤镜检查结果和疼痛评分来评估治疗效果和安全性。
该研究招募了14名参与者，共治疗24个斑块。观察到显著的毛发再生，平均再生量表（RGS）在16 - 24周时增加到2.4，在24 - 36周时达到4。皮肤镜分析显示黑点和黄点减少，而毳毛增加。整个治疗过程中平均疼痛评分保持较低，范围为1.00至3.00，这突出了该治疗方法与传统皮损内注射相比具有良好的耐受性。
基于微针贴片的皮质类固醇给药显示出与皮损内注射皮质类固醇相当的疗效，其额外优势在于减少了与治疗相关的疼痛，并可能提高患者的依从性。
